Cellectics – HealthQuill

About Us

Bharti Rana Jayshankar – Founder

She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.

Jay Shankar – Co-founder

He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.

Contact Info

info@healthquill.com

AstraZeneca signed a $245 million deal with a French clinical-stage biotechnology firm, Cellectis, to speed up therapeutics in oncology, immunology and rare diseases.

AstraZeneca inks $245 million deal with Cellectis for rare diseases

HQ Team November 1, 2023: AstraZeneca signed a $245 million deal with a French clinical-stage biotechnology firm, Cellectis, to speed up therapeutics in.

by HealthQuill
November 1, 2023
0 Comments

About Us

Contact Info

Follow Us

AstraZeneca inks $245 million deal with Cellectis for rare diseases